ADMA BIOLOGICS, INC. ADMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
5/9
Piotroski F — financial health
8.8
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $510.2M | $146.9M | $292.8M | $27.8M | $477.3M |
| 2024 | $426.5M | $197.7M | $219.6M | $110.4M | $349.0M |
| 2023 | $258.2M | -$28.2M | $88.9M | $4.0M | $135.2M |
| 2022 | $154.1M | -$65.9M | $35.3M | -$73.4M | $152.0M |
| 2021 | $80.9M | -$71.6M | $1.2M | -$125.9M | $141.2M |
| 2020 | $42.2M | -$75.7M | -$19.1M | -$114.7M | $88.2M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.8 (safe)
- Working capital / assets 0.636
- Retained earnings / assets -0.259
- EBIT / assets 0.307
- Equity / liabilities 3.249
Source: SEC EDGAR filings · CIK 0001368514 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.